A quantitative approach to the determination of antigen in immune complexes.
Immune complexes are present in the circulation of healthy individuals and the formation of such complexes is part of a normal immune process. During some pathological conditions, significant amounts of immune complexes are formed and deposited in the kidney and other tissues, causing severe injury. Since the levels of immune complexes can provide valuable prognostic information, dozens of methods have been developed to detect and quantify these complexes. However, many of these methods are non-specific, not quantitative, and give false-positive results. Methods based on detecting the antigen portion of immune complexes can yield more precise information about circulating immune complexes. We have used a quantitative dot-blot assay, which permits detection of antigen even if buried, to determine the levels of antigen in circulating immune complexes. In healthy donors, significant amounts of immune complexes containing DNA and beta(2)-glycoprotein I were detected (natural immune complexes). Natural immune complexes with Lewis X antigen were also observed in the circulation of healthy persons. In experimentally induced murine systemic lupus erythematosus (SLE) and SLE patients, there was a correlation between the clinical manifestations and the levels of DNA in the circulating immune complexes. At severe SLE flares, the level of DNA in circulating immune complexes decreased, probably due to tissue deposition of immune complexes. The low levels of DNA in immune complexes circulating in SLE patients correlated with low serum concentrations of the complement component C1q. No direct correlation was found between the levels of circulating anti-dsDNA antibodies and DNA in immune complexes. Thus, quantitation of antigen levels in circulating immune complexes can be used to determine the prognosis of autoimmune diseases.
Nezlin
R
R
Department of Immunology, Weizmann Institute of Science, Rehovot, Israel. roald.nezlin@weizmann.ac.il
D000328:Adult; D000818:Animals; D000936:Antigen-Antibody Complex / Q000032:analysis* / Q000097:blood; D000941:Antigens / Q000032:analysis* / Q000097:blood; D001323:Autoantibodies / Q000032:analysis / Q000097:blood; D001327:Autoimmune Diseases / Q000276:immunology; D004247:DNA / Q000032:analysis / Q000097:blood / Q000276:immunology; D006023:Glycoproteins / Q000032:analysis / Q000097:blood / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate; D015151:Immunoblotting / Q000379:methods* / Q000706:statistics & numerical data; D016256:Lewis X Antigen / Q000032:analysis / Q000097:blood; D008180:Lupus Erythematosus, Systemic / Q000276:immunology; D051379:Mice; D011379:Prognosis; D053482:beta 2-Glycoprotein I
D000936:Antigen-Antibody Complex; D000941:Antigens; D001323:Autoantibodies; D006023:Glycoproteins; D016256:Lewis X Antigen; D053482:beta 2-Glycoprotein I; D004247:DNA